Pancreatic Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pages: 79 Published: April 13, 2022 Report Code: GDHC054CL

  • Overview
  • Contents
  • FAQ
  • Listen
    iSpeech

Pancreatic cancer is the seventh leading cause of cancer deaths worldwide. Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. These accumulating cells form a tumor. Untreated pancreatic cancer spreads to nearby organs and blood vessels. Pancreatic adenocarcinoma (PDAC) or pancreatic exocrine cancer is the most common type of pancreatic cancer and begins in the cells that line the ducts of the pancreas.

The pancreatic cancer marketed and pipeline drugs assessment report provides a data-driven overview of the current and future competitive landscape in pancreatic cancer therapeutics.

Pancreatic Cancer Marketed and Pipeline Drugs Market Overview by Mechanism of Action

The major marketed and pipeline drugs for treating pancreatic cancer are transporter inhibitor, receptor agonist, receptor antagonist, ion channel blocker, enzyme inhibitor, receptor modulator, ligand inhibitor, cells & cell organelle disrupter, receptor inhibitor, cytotoxic, biological factor activator, enzyme replacement, protein & peptide inhibitor, genes, nucleic acids & related components inhibitor, biological factor inhibitor, protein & peptide activator, enzyme activator, antigen inhibitor, ligand depletor, and genes, nucleic acids & related components activator.

Pancreatic Cancer Marketed and Pipeline Drugs Market Analysis by Mechanism of Action

Pancreatic Cancer Marketed and Pipeline Drugs Market Analysis by Mechanism of Action

For more mechanism of action insights, download a free report sample

Pancreatic Cancer Marketed and Pipeline Drugs Market Overview by Routes of Administration

The major marketed and pipeline drugs for treating pancreatic cancer are oral therapies, injections, suppository therapies, topical therapies, and inhalational therapies.

Pancreatic Cancer Marketed and Pipeline Drugs Market Analysis by Routes of Administration

Pancreatic Cancer Marketed and Pipeline Drugs Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Market Report Scope

Major Mechanism of Action Transporter Inhibitor, Receptor Agonist, Receptor Antagonist, Ion Channel Blocker, Enzyme Inhibitor, Receptor Modulator, Ligand Inhibitor, Cells & Cell Organelle Disrupter, Receptor Inhibitor, Cytotoxic, Biological Factor Activator, Enzyme Replacement, Protein & Peptide Inhibitor, Genes, Nucleic Acids & Related Components Inhibitor, Biological Factor Inhibitor, Protein & Peptide Activator, Enzyme Activator, Antigen Inhibitor, Ligand Depletor, and Genes, Nucleic Acids & Related Components Activator
Major Routes of Administration Oral Therapies, Injections, Suppository Therapies, Topical Therapies, and Inhalational Therapies

Scope

GlobalData’s Pancreatic cancer Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the pancreatic cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Overview by Molecule Type

4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

5.1 Late-stage Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Mechanism of Action

5.4 Overview by Route of Administration

5.5 Overview by Molecule Type

5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently Asked Questions

The major marketed and pipeline drugs for treating pancreatic cancer are transporter inhibitor, receptor agonist, receptor antagonist, ion channel blocker, enzyme inhibitor, receptor modulator, ligand inhibitor, cells & cell organelle disrupter, receptor inhibitor, cytotoxic, biological factor activator, enzyme replacement, protein & peptide inhibitor, genes, nucleic acids & related components inhibitor, biological factor inhibitor, protein & peptide activator, enzyme activator, antigen inhibitor, ligand depletor, and genes, nucleic acids & related components activator.

The major marketed and pipeline drugs for treating pancreatic cancer are oral therapies, injections, suppository therapies, topical therapies, and inhalational therapies.

$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.